EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

2014 • 26,824 citations

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

2010 • 21,372 citations

TNM Classification of Malignant Tumours

1987 • 16,209 citations

TNM Classification of Malignant Tumors

1998 • 5,989 citations

Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC Trials

2006 • 2,702 citations

Epidemiology and Risk Factors of Urothelial Bladder Cancer

2012 • 1,914 citations

Intravesical Bacillus Calmette-Guerin Reduces the Risk of Progression in Patients with Superficial Bladder Cancer: A Meta-analysis of the Published Results of Randomized Clinical Trials

2002 • 1,248 citations

Association Between Smoking and Risk of Bladder Cancer Among Men and Women

2011 • 979 citations

WHO Classification of of Tumours of the Urinary System and Male Genital Organs

2016 • 855 citations

A SINGLE IMMEDIATE POSTOPERATIVE INSTILLATION OF CHEMOTHERAPY DECREASES THE RISK OF RECURRENCE IN PATIENTS WITH STAGE Ta T1 BLADDER CANCER: A META-ANALYSIS OF PUBLISHED RESULTS OF RANDOMIZED CLINICAL TRIALS

2004 • 733 citations

Variability in the Recurrence Rate at First Follow-up Cystoscopy after TUR in Stage Ta T1 Transitional Cell Carcinoma of the Bladder: A Combined Analysis of Seven EORTC Studies

2002 • 652 citations

An Individual Patient Data Meta-Analysis of the Long-Term Outcome of Randomised Studies Comparing Intravesical Mitomycin C versus Bacillus Calmette-Guérin for Non–Muscle-Invasive Bladder Cancer

2009 • 606 citations

Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in Patients Treated With Bacillus Calmette-Guerin: The CUETO Scoring Model

2009 • 558 citations

Intravesical Bacillus Calmette-Guerin Versus Mitomycin C For Superficial Bladder Cancer: A Formal Meta-Analysis of Comparative Studies on Recurrence and Toxicity

2003 • 524 citations

Urine Markers for Bladder Cancer Surveillance: A Systematic Review

2005 • 509 citations

Guidelines on Bladder Cancer

2002 • 471 citations

Intravesical bacille calmette-guérin versus mitomycin c in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression

2004 • 447 citations

Final Results of an EORTC-GU Cancers Group Randomized Study of Maintenance Bacillus Calmette-Guérin in Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Urinary Bladder: One-third Dose Versus Full Dose and 1 Year Versus 3 Years of Maintenance

2012 • 441 citations

Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers

2005 • 428 citations

Long-Term Efficacy Results of EORTC Genito-Urinary Group Randomized Phase 3 Study 30911 Comparing Intravesical Instillations of Epirubicin, Bacillus Calmette-Guérin, and Bacillus Calmette-Guérin plus Isoniazid in Patients with Intermediate- and High-Risk Stage Ta T1 Urothelial Carcinoma of the Bladder

2009 • 399 citations

A Prospective European Organization for Research and Treatment of Cancer Genitourinary Group Randomized Trial Comparing Transurethral Resection Followed by a Single Intravesical Instillation of Epirubicin or Water in Single Stage Ta, T1 Papillary Carcinoma of the Bladder

1993 • 367 citations

BACILLUS CALMETTE-GUERIN VERSUS CHEMOTHERAPY FOR THE INTRAVESICAL TREATMENT OF PATIENTS WITH CARCINOMA IN SITU OF THE BLADDER: A META-ANALYSIS OF THE PUBLISHED RESULTS OF RANDOMIZED CLINICAL TRIALS

2005 • 366 citations

Detection of Bladder Cancer Using a Point-of-Care Proteomic Assay

2005 • 360 citations

Intravesical bacillus Calmette‐Guérin is superior to mitomycin C in reducing tumour recurrence in high‐risk superficial bladder cancer: a meta‐analysis of randomized trials

2004 • 333 citations

The Effect of Intravesical Mitomycin C on Recurrence of Newly Diagnosed Superficial Bladder Cancer: A Further Report with 7 Years of Followup

1996 • 325 citations

Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials

2006 • 310 citations

Detrusor Muscle in the First, Apparently Complete Transurethral Resection of Bladder Tumour Specimen Is a Surrogate Marker of Resection Quality, Predicts Risk of Early Recurrence, and Is Dependent on Operator Experience

2009 • 308 citations

Methods to Improve Efficacy of Intravesical Mitomycin C: Results of a Randomized Phase III Trial

2001 • 299 citations

Photodynamic Diagnosis in Non–Muscle-Invasive Bladder Cancer: A Systematic Review and Cumulative Analysis of Prospective Studies

2009 • 291 citations

A Review of Current Guidelines and Best Practice Recommendations for the Management of Nonmuscle Invasive Bladder Cancer by the International Bladder Cancer Group

2011 • 285 citations

A systematic review of intravesical bacillus Calmette‐Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer

2001 • 280 citations

Maintenance Bacillus Calmette-Guerin for Ta T1 Bladder Tumors Is Not Associated with Increased Toxicity: Results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial

2003 • 274 citations

Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial

2005 • 267 citations

Surveillance for Recurrent Bladder Cancer Using a Point-of-Care Proteomic Assay

2006 • 264 citations

The Effect of Repeat Transurethral Resection on Recurrence and Progression Rates in Patients With T1 Tumors of the Bladder Who Received Intravesical Mitomycin: A Prospective, Randomized Clinical Trial

2006 • 244 citations

Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon α-2B for reducing recurrence of superficial bladder cancer☆

2006 • 238 citations

Female Gender and Carcinoma In Situ in the Prostatic Urethra Are Prognostic Factors for Recurrence, Progression, and Disease-Specific Mortality in T1G3 Bladder Cancer Patients Treated With Bacillus Calmette-Guérin

2011 • 227 citations

Occupational cancer burden in Great Britain

2012 • 226 citations

Differences Between Local and Review Urinary Cytology in Diagnosis of Bladder Cancer. An Interobserver Multicenter Analysis

2002 • 214 citations

High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder

2005 • 211 citations

Long‐term follow‐up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette‐Guérin with a reduced dose of 27 mg in superficial bladder cancer

2002 • 205 citations

Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: Systematic review and meta-analysis

2011 • 193 citations

A Multicentre, Randomised Prospective Trial Comparing Three Intravesical Adjuvant Therapies for Intermediate-Risk Superficial Bladder Cancer: Low-Dose Bacillus Calmette-Guerin (27 mg) versus Very Low-Dose Bacillus Calmette-Guerin (13.5 mg) versus Mitomycin C

2007 • 193 citations

The Value of a Second Transurethral Resection in Evaluating Patients with Bladder Tumours

2003 • 192 citations

The Schedule and Duration of Intravesical Chemotherapy in Patients with Non–Muscle-Invasive Bladder Cancer: A Systematic Review of the Published Results of Randomized Clinical Trials

2008 • 188 citations

The Role of a Combined Regimen With Intravesical Chemotherapy and Hyperthermia in the Management of Non-muscle-invasive Bladder Cancer: A Systematic Review

2011 • 187 citations

HAS A 3-FOLD DECREASED DOSE OF BACILLUS CALMETTE-GUERIN THE SAME EFFICACY AGAINST RECURRENCES AND PROGRESSION OF T1G3 AND TIS BLADDER TUMORS THAN THE STANDARD DOSE? RESULTS OF A PROSPECTIVE RANDOMIZED TRIAL

2005 • 185 citations

Long-Term Decrease in Bladder Cancer Recurrence with Hexaminolevulinate Enabled Fluorescence Cystoscopy

2012 • 183 citations

Trends in Mortality From Urologic Cancers in Europe, 1970–2008

2011 • 182 citations

Should All Patients with Non–Muscle-Invasive Bladder Cancer Receive Early Intravesical Chemotherapy after Transurethral Resection? The Results of a Prospective Randomised Multicentre Study

2009 • 173 citations

UPPER URINARY TRACT TUMORS AFTER PRIMARY SUPERFICIAL BLADDER TUMORS: PROGNOSTIC FACTORS AND RISK GROUPS

2000 • 172 citations

Urinary Markers in Bladder Cancer

2007 • 172 citations

Original Articles: Bladder Cancer: Intravesical Adjuvant Chemotherapy for Superficial Transitional Cell Bladder Carcinoma: Results of 2 European Organization for Research and Treatment of Cancer Randomized Trials With Mitomycin C and Doxorubicin Comparing Early Versus Delayed Instillations and Short-Term Versus Long-Term Treatment

1995 • 171 citations

Treatment Paradigm Shift May Improve Survival of Patients With High Risk Superficial Bladder Cancer

2007 • 170 citations

Diagnosis of urothelial carcinoma from urine

2009 • 166 citations

Significance of Bladder Biopsies in Ta,T1 Bladder Tumors: A Report from the EORTC Genito-Urinary Tract Cancer Cooperative Group

1999 • 164 citations

Gemcitabine versus bacille Calmette‐Guérin after initial bacille Calmette‐Guérin failure in non‐muscle‐invasive bladder cancer

2010 • 159 citations

Factors Explaining Recurrence in Patients Undergoing Chemoimmunotherapy Regimens for Frequently Recurring Superficial Bladder Carcinoma

2002 • 158 citations

Prognostic Accuracy of Individual Uropathologists in Noninvasive Urinary Bladder Carcinoma: A Multicentre Study Comparing the 1973 and 2004 World Health Organisation Classifications

2009 • 153 citations

MULTIVARIATE ANALYSIS OF CLINICAL PARAMETERS OF SYNCHRONOUS PRIMARY SUPERFICIAL BLADDER CANCER AND UPPER URINARY TRACT TUMOR

2005 • 150 citations

Follow-up After Surgical Treatment of Bladder Cancer: A Critical Analysis of the Literature

2012 • 149 citations

Declining mortality from bladder cancer in Europe

2007 • 137 citations

Management of Low Grade Papillary Bladder Tumors

2007 • 136 citations

Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis.

2001 • 135 citations

Long-term Efficacy of Maintenance Bacillus Calmette-Guérin versus Maintenance Mitomycin C Instillation Therapy in Frequently Recurrent TaT1 Tumours without Carcinoma In Situ: A Subgroup Analysis of the Prospective, Randomised FinnBladder I Study with a 20-Year Follow-up

2009 • 130 citations

Handling and Pathology Reporting of Specimens with Carcinoma of the Urinary Bladder, Ureter, and Renal Pelvis

2003 • 128 citations

Prognostic Significance of the 2004 WHO/ISUP Classification for Prediction of Recurrence, Progression, and Cancer-Specific Mortality of Non–Muscle-Invasive Urothelial Tumors of the Urinary Bladder

2010 • 127 citations

Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma : results of 2 european organization for research and treatment of cancer randomized trials with Mitomycin C and Doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment

1995 • 124 citations

Cystoscopy Revisited as the Gold Standard for Detecting Bladder Cancer Recurrence: Diagnostic Review Bias in the Randomized, Prospective CEFUB Trial

2009 • 122 citations

THE ROLE AND IMPACT OF PATHOLOGY REVIEW ON STAGE AND GRADE ASSESSMENT OF STAGES TA AND T1 BLADDER TUMORS: A COMBINED ANALYSIS OF 5 EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER TRIALS

2000 • 122 citations

Transurethral Resection of Non–Muscle-Invasive Bladder Transitional Cell Cancers With or Without 5-Aminolevulinic Acid Under Visible and Fluorescent Light: Results of a Prospective, Randomised, Multicentre Study

2009 • 120 citations

Combined Thermo-Chemotherapy for Recurrent Bladder Cancer After Bacillus Calmette-Guerin

2009 • 119 citations

One Immediate Postoperative Instillation of Chemotherapy in Low Risk Ta, T1 Bladder Cancer Patients. Is it Always Safe?

2004 • 117 citations

Cystectomy in Patients with High Risk Superficial Bladder Tumors Who Fail Intravesical BCG Therapy:

2005 • 117 citations

Watchful Waiting Policy in Recurrent Ta G1 Bladder Tumors

2006 • 115 citations

Clinical Practice Recommendations for the Prevention and Management of Intravesical Therapy–Associated Adverse Events

2008 • 113 citations

Detection and clinical outcome of urinary bladder cancer with 5‐aminolevulinic acid‐induced fluorescence cystoscopy

2010 • 113 citations

A SURVEILLANCE SCHEDULE FOR G1Ta BLADDER CANCER ALLOWING EFFICIENT USE OF CHECK CYSTOSCOPY AND SAFE DISCHARGE AT 5 YEARS BASED ON A 25-YEAR PROSPECTIVE DATABASE

2005 • 112 citations

Good quality white‐light transurethral resection of bladder tumours (GQ‐WLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new non‐muscle‐invasive bladder cancer: validation across time and place and recommendation for benchmarking

2011 • 110 citations

Bacillus Calmette-Guérin Is Superior to a Combination of Epirubicin and Interferon-α2b in the Intravesical Treatment of Patients with Stage T1 Urinary Bladder Cancer. A Prospective, Randomized, Nordic Study

2009 • 102 citations

Meta‐analysis: does lidocaine gel before flexible cystoscopy provide pain relief?

2009 • 101 citations

Re: A Single Instillation of Epirubicin After Transurethral Resection of Bladder Tumors Prevents Only Small Recurrences

2008 • 99 citations

Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer

2008 • 98 citations

The Mechanism of Human Bladder Tumor Implantation in an in Vitro Model

1986 • 97 citations

Impact of Previous Bacille Calmette-Guérin Failure Pattern on Subsequent Response to Bacille Calmette-Guérin Plus Interferon Intravesical Therapy

2008 • 92 citations

The WHO classification of 1973 is more suitable than the WHO classification of 2004 for predicting survival in pT1 urothelial bladder cancer

2010 • 92 citations

A Single Instillation of Epirubicin After Transurethral Resection of Bladder Tumors Prevents Only Small Recurrences

2007 • 89 citations

Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer

2011 • 88 citations

Original Articles

1995 • 82 citations

Urothelial Carcinoma of the Prostate

2007 • 81 citations

The Pathologist’s Mean Grade Is Constant and Individualizes the Prognostic Value of Bladder Cancer Grading

2009 • 77 citations

Treatment Options Available for Bacillus Calmette-Guérin Failure in Non–muscle-invasive Bladder Cancer

2012 • 76 citations

Photodynamic Diagnosis (5-Aminolevulinic Acid) of Transitional Cell Carcinoma After Bacillus Calmette-Guérin Immunotherapy and Mitomycin C Intravesical Therapy

2009 • 75 citations

Is Routine Excretory Urography Necessary at First Diagnosis of Bladder Cancer?

1997 • 72 citations

Risk Factors for Mucosal Prostatic Urethral Involvement in Superficial Transitional Cell Carcinoma of the Bladder

2005 • 66 citations

The value of extended transurethral resection of bladder tumour (TURBT) in the treatment of bladder cancer

2012 • 65 citations

Hexylaminolaevulinate fluorescence cystoscopy in patients previously treated with intravesical bacille Calmette‐Guérin

2009 • 64 citations

Safety and Efficacy of Intravesical Bacillus Calmette-Guerin Instillations in Steroid Treated and Immunocompromised Patients

2006 • 60 citations

Urinary Cytology and Quantitative BTA and UBC Tests in Surveillance of Patients with pTapT1 Bladder Urothelial Carcinoma

2008 • 60 citations

Clinical Outcomes of Primary Bladder Carcinoma In Situ in a Contemporary Series

2010 • 58 citations

Pathological stage review is indicated in primary pT1 bladder cancer

2010 • 57 citations

INHIBITION OF TUMOR IMPLANTATION BY INTRAVESICAL GEMCITABINE IN A MURINE MODEL OF SUPERFICIAL BLADDER CANCER

2005 • 57 citations

Cytology and Urinary Markers for the Diagnosis of Bladder Cancer

2009 • 56 citations

Screening for bladder cancer: a perspective

2007 • 54 citations

Long-term follow-up of a randomized prospective trial comparing a standard 81mg dose of intravesical bacille calmette-guérin with a reduced dose of 27mg in superficial bladder cancer.

2003 • 53 citations

Updated concepts and treatment of carcinoma in situ

1998 • 53 citations

Recurrence at Three Months and High-grade Recurrence as Prognostic Factor of Progression in Multivariate Analysis of T1G2 Bladder Tumors

2009 • 50 citations

Effect of Prophylactic Treatment with Intravesical Epirubicin on Recurrence of Superficial Bladder Cancer—The 6th Trial of the Japanese Urological Cancer Research Group (JUCRG):

2004 • 50 citations

Should Follow-up Cystoscopy in Bacillus Calmette-Guérin–Treated Patients Continue After Five Tumour-Free Years?

2011 • 43 citations

Extravesical Involvement in Patients with Bladder Carcinoma In Situ: Biological and Therapy Implications

1996 • 43 citations

Clinical Reliability of the 2004 WHO Histological Classification System Compared With the 1973 WHO System for Ta Primary Bladder Tumors

2011 • 42 citations

Review pathology in a diagnostic bladder cancer trial: Effect of patient risk category

2006 • 33 citations

REVIEW PATHOLOGY IN A DIAGNOSTIC BLADDER CANCER TRIAL: THE IMPACT OF PATIENT RISK CATEGORY

2006 • 30 citations

Intravesical Bacillus Calmette-Guérin Outcomes in Patients With Bladder Cancer and Asymptomatic Bacteriuria

2011 • 29 citations

Re: Richard J. Sylvester, Maurizio A. Brausi, Wim J. Kirkels, et al Long-Term Efficacy Results of EORTC Genito-Urinary Group Randomized Phase 3 Study 30911 Comparing Intravesical Instillations of Epirubicin, Bacillus Calmette-Guerin, and Bacillus Calmette-Guerin plus Isoniazid in Patients with Intermediate- and High-Risk Stage Ta T1 Urothelial Carcinoma of the Bladder. Eur Urol 2010;57:766-73 Reply

2010 • 20 citations

INTERLEUKIN-4 ACTIVATES ANDROGEN RECEPTOR THROUGH CBP/p300 MEDIATED ACETYLATION AND STIMULATES ANDROGEN INDEPENDENT GROWTH

2008 • 12 citations

Deleted Work

1955 • 0 citations